A comparative evaluation of gene transfer into blood cells using the same retroviral backbone for independent expression of the EGFP and ΔLNGFR marker genes

Haematologica

Volumn 85, Issue 7, 2000, Pages 680-689

  Giaretta, I ^a   Madeo, D ^a   Bonaguro, R ^a   Cappellari, A ^a   Rodeghiero, F ^a   Palu, G ^a  

^a Department of Histology   (Italy)

Author keywords

LNGFR; EGFP; Hematopoietic cells; Packaging clones; Retrovirus mediated gene transfer

Indexed keywords

CD34 ANTIGEN; GREEN FLUORESCENT PROTEIN; NERVE GROWTH FACTOR; VIRUS VECTOR;

ARTICLE; BLOOD CELL; FLOW CYTOMETRY; GENE EXPRESSION; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC CELL; HUMAN; MARKER GENE; MOLECULAR CLONING; NONHUMAN; POLYMERASE CHAIN REACTION; RETROVIRUS; START CODON; VIRUS TITRATION;

CELL LINE; EVALUATION STUDIES; FLOW CYTOMETRY; FLUORESCENT DYES; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC MARKERS; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HEMATOPOIETIC STEM CELLS; HUMANS; LUMINESCENT PROTEINS; PYRIDINIUM COMPOUNDS; RECEPTOR, NERVE GROWTH FACTOR; RETROVIRIDAE;

EID: 0033862183     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation
2. Gene marking to determine whether autologous marrow infusion restores long-term haemopoiesis in cancer patients
3. An approach for the analysis of relapse and marrow reconstitution after autologous marrow transplantation using retrovirus-mediated gene transfer
4. Amendment to clinical research projects. Genetic marking with retroviral vectors to study the feasibility of stem cell gene transfer and the biology of hematopoietic reconstitution after autologous transplantation in multiple myeloma, chronic myelogenous leukemia, or metastatic breast cancer
5. Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission
6. In vivo trafficking of adoptively transferred interleukin-2 expanded tumor-infiltrating lymphocytes and peripheral blood lymphocytes. Results of a double gene marking trial
7. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation
8. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia
9. Analysis of optimal conditions for retroviral-mediated transduction of primitive human hematopoietic cells
10. Identification of primitive human hematopoietic cells capable of repopulating NOD/SCID mouse bone marrow: Implications for gene therapy
11. Highly efficient transduction of the green fluorescent protein gene in human umbilical cord blood stem cells capable of cobblestone formation in long-term cultures and multilineage engraftment of immunodeficient mice
12. High efficiency gene transfer to human hematopoietic SCID-repopulating cells under serum-flee conditions
13. Optimization of retroviral-mediated gene transfer to human NOD/SCID mouse repopulating cord blood cells through a systematic analysis of protocol variables
14. Retrovirally marked CD34-enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation
15. Use of double marking with retroviral vectors to determine rate of reconstitution of untreated and cytokine expanded CD34+ selected marrow cells in patients undergoing autologous bone marrow transplantation
16. Retroviral gene transfer in autologous bone marrow transplantation For adult acute leukemia
17. Retroviral transfer of the glucocerebrosidase gene into CD34+ cells from patients with Gaucher disease: In vivo detection of transduced cells without myeloablation
18. Retroviral vectors For use in human gene therapy for cancer, Gaucher disease, and arthritis
19. Gene marking
20. Retroviral mediated gene transfer into bone marrow progenitor cells: Use of β-galactosidase as a selectable marker
21. Hematological reconstitution and gene therapy: Retroviral transfer of the bacterial β-galactosidase activity into human hematopoietic CD34+ cell populations and into T lymphocytes derived from the peripheral blood
22. An enhanced green fluorescent protein allows sensitive detection of gene transfer in mammalian cells
23. Optimized codon usage and chromophore mutations provide enhanced sensitivity with the green fluorescent protein
24. Green fluorescent protein variants as markers of retroviral-mediated gene transfer in primary hematopoietic cells and cell lines
25. p75 and Trk: A two-receptor system
26. Expression and functionality of the trkA proto-oncogene product/NGF receptor in undifferentiated hematopoietic cells
27. Nerve growth factor is an autocrine survival factor for memory B lymphocytes
28. Cell-surface marking of CD(34+)-restricted phenotypes of human hematopoietic progenitor cells by retrovirus-mediated gene transfer
29. Selective immunoaffinity-based enrichment of CD34+ cells transduced with retroviral vectors containing an intracytoplasmatically truncated version of the human low-ffinity nerve growth factor receptor (ΔLNGFR) gene
30. Multiparameter-fluorescence activated cell sorting analysis of retroviral vector gene transfer into primitive umbilical cord blood cells
31. Sustained gene expression in retrovirally transduced, engrafting human hematopoietic stem cells and their lympho-myeloid progeny
32. Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens
33. Positive selection of viable cell populations using avidin-biotin immunoadsorption
34. Construction and use of a safe and efficient amphotropic packaging cell line
35. Production of high-titer helper-free retroviruses by transient transfection
36. Retroviral-mediated gene transfer into hepatocytes in vivo
37. High-titer retroviral vectors containing the enhanced green fluorescent protein gene for efficient expression in hematopoietic cells
38. Increased levels of spliced RNA account for augmented expression from the MFG retroviral vector in hematopoietic cells
39. Analysis of the relative level of gene expression from different retroviral vectors used for gene therapy
40. Enhanced green fluorescent protein as selectable marker of retroviral-mediated gene transfer in immature hematopoietic bone marrow cells
41. Enhanced green fluorescent protein as an efficient reporter gene for retroviral transduction of human multipotent lymphoid precursors
42. Green fluorescent protein as a selectable marker of fibronectin-facilitated retroviral gene transfer in primary human T lymphocytes
43. Lack of expression from a retroviral vector after transduction of murine hematopoietic stem cells is associated with methylation in vivo
44. Green fluorescent protein retroviral vectors: Low titer and high recombination frequency suggest a selective disadvantage
45. Measuring gene-transfer efficiency
46. Retrovirus infection: Effect of time and target cell number
47. The physico-chemical factors that govern retrovirus-mediated gene transfer
48. Transduction efficiency of cell lines and hematopoietic stem cells correlates with retrovirus receptor mRNA levels